BioCentury | May 21, 2019
Clinical News

BioCryst makes case for oral HAE therapy even as Phase III data disappoint investors

...the Shire plc unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK); Shire's C1 esterase inhibitor Cinryze...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...$51 million in 3Q18 sales put it on track to surpass the market leader, Takeda's Cinryze...
BioCentury | Sep 21, 2018
Clinical News

FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

...Shire plc (LSE:SHP; NASDAQ:SHPG) markets the human mAb against plasma kallikrein (KLKB1) as well as Cinryze...
BioCentury | Sep 19, 2018
Company News

FDA wants extra trial for Pharming's Ruconest as HAE prophylactic

...Shire plc (LSE:SHP; NASDAQ:SHPG) markets the human mAb against plasma kallikrein (KLKB1) as well as Cinryze...
BioCentury | Aug 31, 2018
Clinical News

FDA approves Shire's Takhzyro, first mAb to prevent HAE

...a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze...
BioCentury | Aug 23, 2018
Company News

FDA approves Shire’s Takhzyro, first mAb to prevent HAE

...a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze...
BioCentury | Aug 4, 2018
Finance

Functions of formulation

...Recombinant human α 1-antitrypsin $9 $54 $63 11% 06/06/11 ViroPharma Inc. (B) 1 Inflammation Subcutaneous Cinryze...
BioCentury | Mar 2, 2018
Clinical News

Priority review for Shire's HAE prophylactic

...a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze...
...four days. Lanadelumab, which is dosed every two weeks, could provide a dosing benefit over Cinryze...
BioCentury | Feb 23, 2018
Company News

Priority Review for Shire's HAE prophylactic

...a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze...
...four days. Lanadelumab, which is dosed every two weeks, could provide a dosing benefit over Cinryze...
BioCentury | Jan 27, 2018
Finance

All together now

...Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2014 for $4.2 billion to obtain ViroPharma’s HAE prophylactic Cinryze...
Items per page:
1 - 10 of 214